Members of BioTime's management, Adi Mohanty, Co-CEO and David Schlachet, director of the company, were invited to participate in the opening bell ceremony at TASE.
BioTime, included in the TA-75 and TA-100 TASE indices, is a dually listed company also traded on NYSE MKT with a market value of approximately $ 400 million. The company develops medical products based on stem cell research.
Adi Mohanty, BioTime's Co-CEO: "We are pleased to mark a year and a half since BioTime's dual listing on the TASE, as well as the opening of the new production center in Jerusalem. These events constitute significant milestones for the company that will provide access for millions of patients facing complex diseases to stem cell based treatments.
We value our partnership with financial, government and academic institutions in Israel, which allow us to fulfill our commitment to manufacture a stem cell based treatments in Israel. We anticipate tremendous potential for our products as we plan to move from the development phase to distribution".
Aya Ben David Ashbel, Senior Vice President, General Counsel and Head of the Legal Department: "We're proud that the company has chosen to establish its manufacturing center in Jerusalem and to deepen its activity in Israel even further. We view this as a vote of confidence in the Israeli capital market and economy".
From right to left: Ittai Ben-Zeev, TASE CEO; Ilan Gerzi, Pearl Cohen Zedek Latzer Baratz; David Schlachet, director of the company; Adi Mohanty, co-CEO; and Aya Ben David Ashbel, Senior Vice President, Legal Counsel and Director of Legal Department, TASE.
Photo credit: Guy Assayag.
